UroGen Pharma (URGN) Projected to Post Quarterly Earnings on Monday

UroGen Pharma (NASDAQ:URGN) will likely be releasing its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect UroGen Pharma to post earnings of ($0.83) per share and revenue of $22.71 million for the quarter.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analysts’ expectations of $25.25 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Stock Down 3.0 %

Shares of UroGen Pharma stock opened at $10.35 on Friday. The stock’s 50-day moving average is $10.64 and its 200 day moving average is $10.98. UroGen Pharma has a one year low of $8.94 and a one year high of $20.70. The firm has a market cap of $477.21 million, a price-to-earnings ratio of -3.29 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on URGN shares. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of UroGen Pharma in a report on Monday, April 28th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Thursday. The Goldman Sachs Group cut their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. Finally, Scotiabank initiated coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 target price for the company. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, UroGen Pharma presently has an average rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.